SAN DIEGO—Bariatric surgery and weight loss medications both have been used to reduce mortality risk in patients with liver disease, but recent retrospective studies seem to be swinging the pendulum toward bariatric surgery.
In retrospective studies presented at The Liver Meeting 2024, bariatric surgery was associated with better survival and fewer major adverse cardiac events (MACE) in people with metabolic dysfunction–associated liver disease than treatment with glucagon-like